Skip to content

Study · In vitro (cells) · rat · 1989

3 results

A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide.

Bagley CJ, May BL, Szabo L, McNamara PJ, Ross M, Francis GL, Ballard FJ, Wallace JC

The Biochemical journal1 May 1989Cited by 43 (Europe PMC)

PMID2730580 (opens in a new tab)PMCIDPMC1138570 (opens in a new tab)DOI10.1042/bj2590665 (opens in a new tab)PepBankPUB-02730580
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In rat L6 myoblasts, des-(1-3)-IGF-1 produced half-maximal protein synthesis stimulation at 1.5 ng/ml.

    In plain wordsIn cells, des-(1-3)-IGF-1 reached half-maximal stimulation of protein production at 1.5 ng/ml.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicableProtein synthesis half-maximal response
    Study

    ratn: not reported in source

    L6 myoblasts
    Outcome group
    Protein and amino acid metabolism · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Half-maximal response concentration
    1.5 ng/ml
    Protein synthesis, des-(1-3)-IGF-1

    Source sentences

    Summary
    In a bioassay that measured the stimulation of protein synthesis in rat L6 myoblasts, the concentrations required to produce a half-maximal response were: IGF-1, 13 ng/ml; des-(1)-IGF-1, 10 ng/ml; des-(1-2)-IGF-1, 13 ng/ml; des-(1-3)-IGF-1, 1.5 ng/ml; des-(1-4)-IGF-1, 5.1 ng/ml; des-(1-5)-IGF-1, 1200 ng/ml.
    1 context sentence
    Summary · context
    In order to elucidate the role of the N-terminus of insulin-like growth factor 1 (IGF-1) with respect to its biological properties, we chemically synthesized analogues of IGF-1 truncated by one to five amino acid residues from the N-terminus.
  2. 02LabIn vitro (cells)Activity measurement

    In rat L6 myoblasts at 3 degrees C, des-(1-3)-IGF-1 produced 50% competition for IGF-1 binding at 14 ng/ml.

    In plain wordsIn cells, des-(1-3)-IGF-1 competed for half the labelled IGF-1 binding at 14 ng/ml.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicableCompetition for IGF-1 binding
    Study

    ratn: not reported in source

    L6 myoblasts
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    50% competition concentration
    14 ng/ml
    des-(1-3)-IGF-1, 3 degrees C

    Source sentences

    Summary
    When tested for their abilities to compete with 125I-IGF-1 binding to L6 myoblasts at 3 degrees C, the concentrations required for 50% competition were: IGF-1, des-(1)-IGF-1 and des-(1-2)-IGF-1, 20 ng/ml; des-(1-3)-IGF-1, 14 ng/ml; des-(1-4)-IGF-1, 40 ng/ml; des-(1-5)-IGF-1, greater than 1000 ng/ml.
    1 context sentence
    Summary · context
    In order to elucidate the role of the N-terminus of insulin-like growth factor 1 (IGF-1) with respect to its biological properties, we chemically synthesized analogues of IGF-1 truncated by one to five amino acid residues from the N-terminus.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 03LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cell-free)Activity measurement

    In binding assays, the three longer peptides competed at least 60-fold better than shorter peptides including des-(1-3)-IGF-1.

    In plain wordsIn lab tests, longer IGF peptides competed for binding protein sites more strongly than des-(1-3)-IGF-1.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseBinding protein competition
    Study

    ratn: not reported in source

    L6-conditioned medium and purified MDBK-cell binding protein
    Comparator
    IGF-1, des-(1)-IGF-1 and des-(1-2)-IGF-1
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Relative competition potency
    ≥ 60 fold
    Longer peptides versus three shorter peptides

    Source sentences

    Summary
    In both cases IGF-1, des-(1)-IGF-1 and des-(1-2)-IGF-1 competed for tracer IGF-1 binding at least 60-fold better than did the three shorter peptides.
    2 context sentences
    Summary · context
    This interpretation was confirmed by binding studies with medium conditioned by the L6 myoblasts as well as binding protein purified from MDBK-cell-conditioned medium.
    Summary · context
    In order to elucidate the role of the N-terminus of insulin-like growth factor 1 (IGF-1) with respect to its biological properties, we chemically synthesized analogues of IGF-1 truncated by one to five amino acid residues from the N-terminus.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.